Only an overall 15% net benefit emerges in favour of adjuvant intravesical chemotherapy when compared to transurethral resection alone for the prevention of recurrences of superficial bladder tumors.

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)233-234
Number of pages2
JournalEuropean Urology
Issue number2
Publication statusPublished - Aug 2006

ASJC Scopus subject areas

  • Urology

Cite this